Dalton Medicinal Chemistry Partners Signs Agreement with Boehringer Ingelheim
News Mar 26, 2007
Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces the signing of a Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd.
Dalton Medicinal Chemistry Partners will utilise their medicinal chemistry expertise to design and synthesise novel compounds against a number of antiviral targets selected by Boehringer Ingelheim (Canada) Ltd.
Peter Pekos, President of Dalton Pharma Services, said: "We are pleased to enter this exciting partnership with Boehringer Ingelheim (Canada) Ltd by bringing the added value of our medicinal chemistry capabilities and expertise to their antiviral research projects."
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE